Skip to main content
Quest PharmaTech Inc. logo

Quest PharmaTech Inc. — Investor Relations & Filings

Ticker · QPT ISIN · CA74836M1068 TSXV Manufacturing
Filings indexed 346 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country CA Canada
Listing TSXV QPT

About Quest PharmaTech Inc.

https://questpharmatech.com/

Quest PharmaTech Inc. is a biopharmaceutical company focused on the discovery and development of novel therapeutics. The company's pipeline targets applications in cancer treatment, dermatology, and wound healing, utilizing both proprietary technologies, such as transdermal delivery systems, and strategic investments. A core proprietary asset is the antibody Mab AR 9.6, licensed for targeted cancer therapy against truncated O-glycan on MUC16. Quest also maintains significant ownership interests in associated entities, including OncoVent, and holds convertible bond interests in OncoQuest Pharmaceuticals, Inc. (OQP). These OQP bonds are planned to be exchanged into shares of Canaria Bio, a company developing immunotherapy assets, providing Quest with an expected ownership stake of approximately 23% in Canaria Bio upon conversion.

Recent filings

Filing Released Lang Actions
Other material contracts - English.pdf
Regulatory Filings
2026-05-11 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2025-12-22 English
Interim MD&A - English.pdf
Regulatory Filings
2025-12-22 English
Interim financial statements/report – English.pdf
Regulatory Filings
2025-12-22 English
Interim MD&A - English.pdf
Management Reports Classification · 92% confidence The document is titled “Management’s Discussion & Analysis For the six months ended July 31, 2025,” and contains narrative commentary, analysis of operations, liquidity, risks, and accounting policies prepared alongside unaudited condensed interim consolidated financial statements under IFRS and Canadian securities regulations. It is not merely a brief announcement but the full MD&A section for an interim period. This fits the definition of a Management Report (MDA) rather than an Annual Report, Earnings Release, or simple announcement.
2025-09-26 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 55% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” by the CFO under Canadian National Instrument 52-109. It is an attestation certificate, not the interim financial report or MD&A itself, nor an announcement of a report’s publication. It does not match any specific report category (IR) or announcement (RPA) and thus falls into the general regulatory filings fallback category.
2025-09-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.